VIVISOL Company Profile

Background

VIVISOL, established in 1986, is a leading European provider of home care services specializing in respiratory care, including oxygen therapy, mechanical ventilation, and the diagnosis and treatment of obstructive sleep apnea. The company also offers services in artificial nutrition, telemedicine, medical assistance, care services, and infusion therapy. With over 35 years of experience, VIVISOL has become one of Europe's largest home care groups, operating in 18 countries and serving over 650,000 patients daily.

Key Strategic Focus

VIVISOL's strategic focus includes:

Core Objectives: Enhancing the quality of life for chronic patients through comprehensive home care services.

Areas of Specialization: Respiratory care, mechanical ventilation, sleep-disordered breathing, artificial nutrition, telemedicine, medical assistance, care services, and infusion therapy.

Key Technologies Utilized: Advanced medical devices for respiratory support, telemedicine platforms for remote patient monitoring, and AI-driven solutions for patient compliance.

Primary Markets Targeted: Chronic patients requiring home-based medical care across Europe, with recent expansions into Eastern Europe and the Czech Republic.

Financials and Funding

VIVISOL is a subsidiary of the SOL Group, a multinational operating in the technical, industrial, and medical gases sector. In the first half of 2025, the SOL Group reported consolidated net sales of approximately €875.6 million, with VIVISOL contributing €448.8 million, marking a 14.7% year-on-year increase. The company has demonstrated financial resilience, with a credit rating of B3 and a probability of default of 23.86%, reflecting a moderate level of credit risk.

Pipeline Development

VIVISOL's pipeline development focuses on expanding its service offerings and geographic reach. Notable developments include:

Acquisition of MEDAIR OXIGEN SOLUTION S.R.L.: In 2025, VIVISOL, through its parent company SOL Group, acquired a 70% stake in MEDAIR OXIGEN SOLUTION S.R.L., a Romanian home respiratory care provider, enhancing its presence in Eastern Europe.

Entry into the Czech Market: The SOL Group expanded into the Czech Republic by acquiring 100% of Oxytechnic Spol, a local home care company, further strengthening VIVISOL's market position.

Technological Platform and Innovation

VIVISOL distinguishes itself through:

Proprietary Technologies: Advanced medical devices for respiratory support and telemedicine platforms for remote patient monitoring.

Significant Scientific Methods: Implementation of AI-driven solutions to enhance patient compliance and treatment outcomes.

Leadership Team

VIVISOL operates under the leadership of the SOL Group's executive team, with key figures including:

Aldo Fumagalli Romario: CEO of SOL Group.

Marco Annoni: CEO of SOL Group.

Market Insights and Dynamics

The home care sector is experiencing significant growth due to an aging population and increasing prevalence of chronic diseases. VIVISOL's expansion into Eastern Europe and the Czech Republic positions it to capitalize on these trends.

Competitor Analysis

VIVISOL faces competition from other home care providers such as ProResp, which operates in similar markets.

Strategic Collaborations and Partnerships

VIVISOL has strengthened its market position through strategic partnerships, including:

Acquisition of ITOP S.p.A.: In 2022, SOL Group acquired a 51% stake in ITOP S.p.A., a leading Italian company in the design and production of custom-made aids, prostheses, and orthoses, enhancing VIVISOL's capabilities in orthopedic technology.

Operational Insights

VIVISOL's strategic acquisitions and partnerships have bolstered its service offerings and geographic reach, providing a competitive edge in the home care sector.

Strategic Opportunities and Future Directions

VIVISOL's strategic roadmap includes:

Expansion into New Markets: Continued geographic expansion, particularly in Eastern Europe and the Czech Republic, to tap into emerging markets.

Technological Advancements: Further development and implementation of AI-driven solutions to enhance patient compliance and treatment outcomes.

Service Diversification: Broadening service offerings to include comprehensive home care solutions, integrating respiratory care with other medical services.